한글목차

세계의 류마티스 관절염 치료제 시장 규모는 2024년 285억 달러, 2025년 302억 달러에서 2025년부터 2030년까지 예측 기간 동안 CAGR 6.3%로 추이하고, 2030년에는 411억 달러에 달할 것으로 예측됩니다.

북미 시장은 2024년 155억 달러, 2025년 164억 달러에서 예측 기간 동안 CAGR 6.4%로 추이하고 2030년에는 224억 달러에 달할 것으로 예측되고 있습니다. 아시아태평양 시장은 2024년 42억 달러, 2025년 45억 달러에서 예측 기간 동안 CAGR 7%로 추이하고, 2030년에는 63억 달러에 이를 것으로 예측되고 있습니다.

본 보고서에서는 세계 류마티스 관절염 치료제 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모 추이와 예측, 각종 구분, 지역별 상세 분석 등을 정리했습니다.

목차

제1장 주요 요약

• 시장 전망
• 조사 범위
• 시장 요약

제2장 시장 개요

• 개요
• 거시경제 요인 분석
• 미국 관세가 제약업계에 미치는 영향
• 고령화 인구
• 지정학적 리스크, 무역전쟁, 공급망의 혼란
• 의료비 증가
• Porter's Five Forces 분석

제3장 시장 역학

• 시장 역학
• 시장 성장 촉진요인
• 류마티스 관절염(RA) 치료에서 바이오시밀러 증가
• 류마티스 관절염(RA) 증례 수 증가
• 고령화 인구 증가
• 시장 성장 억제요인
• 특허 독점권 상실
• 류마티스 전문의 부족
• 류마티스 관절염(RA) 치료제의 부작용
• 시장 기회
• 류마티스 관절염(RA) 치료의 기술 진보
• 새로운 표적 요법
• 제조업체의 무기 전략 증가

제4장 규제 상황

• 개요
• 미국
• 생물학적 제형
• 바이오시밀러
• 유럽
• 아시아태평양

제5장 신기술과 파이프라인 분석

• 개요
• AI와 머신러닝(ML)
• 줄기세포요법
• 면역요법
• 파이프라인 분석
• 특허 분석
• 중요 포인트

제6장 시장 세분화 분석

• 세분화의 내역
• 세계의 류마티스 관절염(RA) 치료제 시장 : 치료 유형별
• 중요 포인트
• 질환 수식성 항류마티스제(DMARD)
• 표적 합성 DMARD/JAK 억제제
• 비스테로이드성 항염증제(NSAID)
• 바이오시밀러
• 스테로이드
• 기타
• 세계의 류마티스 관절염(RA) 치료제 시장 : 판매 채널별
• 중요 포인트
• 처방약
• 시판약(OTC)
• 지리적 내역
• 세계의 류마티스 관절염(RA) 치료제 시장 : 지역별
• 중요 포인트
• 북미
• 유럽
• 아시아태평양
• 중동 및 아프리카
• 남미

제7장 경쟁 정보

• 중요 포인트
• 시장 점유율 분석
• 기업 점유율 분석

제8장 류마티스 관절염(RA) 치료제 시장의 지속가능성 : ESG 관점

• ESG: 소개
• 류마티스 관절염 치료제 시장의 지속가능성
• ESG의 관점
• 환경에 미치는 영향
• 사회적 영향
• 거버넌스의 영향
• ESG 위험 평가
• 결론

제9장 부록

• 조사 방법
• 약어
• 출처
• 기업 프로파일
• ABBOTT
• ABBVIE INC.
• AMGEN INC.
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• PFIZER INC.
• SANOFI
• SWEDISH ORPHAN BIOVITRUM AB
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• VIATRIS INC.

영문목차

The global market for rheumatoid arthritis therapies was valued at $28.5 billion in 2024 and is estimated to increase from $30.2 billion in 2025 to reach $41.1 billion by 2030, at a compound annual growth rate (CAGR) of 6.3% from 2025 through 2030.

The North American market for rheumatoid arthritis therapies was valued at $15.5 billion in 2024 and is estimated to increase from $16.4 billion in 2025 to reach $22.4 billion by 2030, at a CAGR of 6.4% from 2025 through 2030.

The Asia-Pacific market for rheumatoid arthritis therapies was valued at $4.2 billion in 2024 and is estimated to increase from $4.5 billion in 2025 to reach $6.3 billion by 2030, at a CAGR of 7% from 2025 through 2030.

Report Scope

The current report will provide detailed information on therapies for rheumatoid arthritis (RA). This report analyzes the market trends of RA therapies, with the base year for the study set at 2024, estimated for 2025, and forecast between 2026 and 2030, including compound annual growth rate (CAGR) for the forecast period and regional markets. The report will highlight current and future market potential and provide a detailed analysis of the competitive environment as well as regulatory scenarios, drivers, restraints, and opportunities. The report also covers the market shares for key producers.

The market scope in this report is segmented into therapies, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), steroids/corticosteroids, biosimilars, and others. It also covers over-the-counter (OTC)- and prescription-based sales channels.

The report covers significant geographical regions: North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. The regional segmentation will offer a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia, and India. For market estimates, data will be provided for 2024 as the base year, with forecasts for 2025 through 2030.

The report aims to:

• Analyze RA therapy types.
• Analyze global market size and segmentation.
• Understand market constraints and drivers.
• Provide detailed market forecasts for 2030.
• Assess market shares, competitiveness, and industry structure.
• Identify potential long-term impacts on the market for RA therapies.

Report Includes

• 94 data tables and 51 additional tables
• In-depth analysis of the global markets for rheumatoid arthritis (RA) treatment therapies
• Analyses of global market trends, with revenue data for 2024, estimates for 2025, forecasts for 2026, and projected CAGRs through 2030
• Estimates of the market's current size and revenue prospects, accompanied by a market share analysis based on therapy type, sales channel and region
• Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors
• Insights derived from Porter's Five Forces model, as well as global supply chain analysis
• Discussion of the key marketed products and products in different stages of clinical development
• An analysis of patents, and emerging trends and developments in patent activity
• Overview of sustainability trends and ESG developments, with consumer attitudes, and the ESG scores and practices of leading companies
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Company profiles of major players within the industry, including AbbVie Inc., Pfizer Inc., Johnson & Johnson Services Inc., Bristol-Myers Squibb Co., Amgen Inc., and F. Hoffmann-La Roche Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Macroeconomic Factor Analysis
• Impact of U.S. Tariffs on the Pharmaceutical Industry
• Aging Population
• Geopolitical Risks, Trade Wars, and Supply Chain Disruptions
• Increasing Healthcare Expenditures
• Porter's Five Forces Analysis
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential for New Entrants
• Threat of Substitutes
• Competitiveness in the Industry

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Increasing Biosimilars for RA Treatment
• Rising Cases of RA
• Increasing Aging Population
• Market Restraints
• Loss of Patent Exclusivity
• Shortage of Rheumatologists
• Side Effects of RA Drugs
• Market Opportunities
• Technological Advances in RA Therapies
• Emerging Targeted Therapies
• Increasing Inorganic Strategies amongst Manufacturers

Chapter 4 Regulatory Landscape

• Overview
• The U.S.
• Biologics
• Biosimilars
• Europe
• Asia-Pacific

Chapter 5 Emerging Technologies and Pipeline Analysis

• Overview
• Artificial Intelligence (AI) and Machine Learning (ML)
• Stem Cell Therapy
• Immunotherapy
• Pipeline Analysis
• Patent Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for RA Therapies by Therapy Type
• Key Takeaways
• Disease-modifying Anti-rheumatic Drugs (DMARDs)
• Targeted Synthetic DMARDs/JAK Inhibitors
• Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
• Biosimilars
• Steroids
• Other Drugs
• Global RA Therapies by Sales Channel
• Key Takeaways
• Prescription Drugs
• Over-the-Counter (OTC) Drugs
• Geographic Breakdown
• Global Market for RA Therapies, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa (MEA)
• South America

Chapter 7 Competitive Intelligence

• Key Takeaways
• Market Share Analysis
• Company Share Analysis

Chapter 8 Sustainability in the RA Therapies Market: An ESG Perspective

• Introduction to ESG
• Sustainability in the Market for RA Therapies
• ESG Perspective
• Environmental Impact
• Social Impact
• Governance Impact
• ESG Risk Ratings
• Conclusion

Chapter 9 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ABBOTT
• ABBVIE INC.
• AMGEN INC.
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• PFIZER INC.
• SANOFI
• SWEDISH ORPHAN BIOVITRUM AB
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• VIATRIS INC.